← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $617B	1,831	+38	+2%	$161B
2	2 Pfizer PFE $169B	1,606	-21	-1%	$133B
3	3 Merck MRK $368B	1,470	+11	+0.8%	$103B
4	4 AbbVie ABBV $508B	1,297	+10	+0.8%	$49B
5	5 Bristol-Myers Squibb BMY $125B	1,188	+9	+0.8%	$53B
6	6 Amgen AMGN $238B	1,062	+30	+3%	$68.7B
7	7 Gilead Sciences GILD $197B	982	+34	+4%	$97.4B
8	8 Novartis NVS $287B	761	-2	-0.3%	$18.4B
9	9 GSK GSK $98.7B	635	-4	-0.6%	$13.4B
10	10 Regeneron Pharmaceuticals REGN $82.9B	414	+43	+12%	$24B
11	11 AstraZeneca AZN $260B	343	+12	+4%	$6.81B
12	12 Myriad Genetics MYGN $419M	267	+6	+2%	$2.45B
13	13 Jazz Pharmaceuticals JAZZ $14B	249	+15	+6%	$4.73B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	198	+4	+2%	$5.52B
15	15 Incyte INCY $23.1B	193	+11	+6%	$5.93B
16	16 Opko Health OPK $1.19B	155	+24	+18%	$571M
17	17 DELISTED Immunogen Inc IMGN	141	+13	+10%	$1.26B
18	18 DELISTED Exact Sciences EXAS	129	+8	+7%	$750M
19	19 Exelixis EXEL $15.6B	126	+5	+4%	$1B
20	SPPI 20 DELISTED Spectrum Pharmaceuticals Inc SPPI	118	-4	-3%	$375M
21	CLVS 21 DELISTED Clovis Oncology, Inc. CLVS	116	+7	+6%	$1.36B
22	22 Halozyme HALO $13.7B	110	0	0%	$862M
23	23 Geron GERN $790M	105	+12	+13%	$139M
24	INFI 24 DELISTED Infinity Pharmaceuticals, Inc. INFI	100	-19	-16%	$836M
25	25 DELISTED Assertio ASRT	98	+13	+15%	$282M